Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
On this video, Kelly L. Stratton, MD, FACS, additional discusses a section 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi) for high-risk prostate...
